Close
Use this page to view details for the decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R).
Use this page to view details for the decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndromes (MDS) (CAG-00415R).
Published: February 13, 2024Written by: Rob LevyWhen Youling Sun was diagnosed in Shanghai, China, with acute myeloid leukemia (AML) in 2018, he called his son,…
Paul V. Viscuse, MD, spotlights key data from the 2024 Genitourinary Cancers Symposium in bladder cancer and renal cell carcinoma.
This report describes the development of an 18-gene urine panel for high-grade prostate cancer and validates its external performance relative to current guideline-endorsed biomarkers.
Sara Corvigno, MD, PhD, expands on an analysis that uncovered the CHIP variants that occurred at a higher frequency in patients with ovarian cancer post-chemotherapy.
Mariana Brandao, MD, PhD, Institute Jules Bordet, Brussels, Belgium, delves into the complexities of defining operability in non-small cell lung cancer (NSCLC), acknowledging the unique…
Debu Tripathy, MD, highlights the potential role and significance of vepdegestrant in pretreated ER-positive/HER2-negative breast cancer.
Supported by an independent educational grant from Servier. Join us for an interactive a nd engaging symposium that takes a deep dive into the latest…
Tune in to this week’s VJHemOnc podcast to learn more about current & emerging treatment options for acute & chronic GvHD, as well as the…
Oliver Dorigo, MD, PhD, discusses the investigation of CRX100 in patients with recurrent, platinum-resistant ovarian cancer.
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.